Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17202 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Kazuki M Matsuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Scleroderma, Systemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to develop and assess the reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract (GIT) Instrument 2.0 (the GIT score), as an evaluation tool for GIT symptoms in systemic sclerosis (SSc). The Japanese version of the GIT score was constructed using the forward‐backward method. The reliability and validity of this instrument were evaluated in a cohort of 38 SSc patients. Correlation analysis was conducted to assess the relationship between the GIT score and existing patient‐reported outcome measures. Additionally, the sensitivity of the GIT score was examined by comparing GIT scores before and after intravenous immunoglobulin (IVIG) administration in 10 SSc‐myositis overlap patients, as IVIG has recently demonstrated effectiveness in alleviating GIT symptoms of SSc. As a result, the Japanese version of the GIT score exhibited internal consistency and a significant association with the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease. Furthermore, the total GIT score, as well as the reflux and distention/bloating subscales, displayed moderate correlations with the EuroQol 5 dimensions (EQ‐5D) pain/discomfort subscale and the Short Form‐36 body pain subscale. Notably, following IVIG treatment, there was a statistically significant reduction in the total GIT score and multiple subscales. We first validated the Japanese version of the GIT score in Japanese SSc patients in real‐world clinical settings. This instrument holds promise for application in future clinical trials involving this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Clinical Cannabinoid Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Kazuki M Matsuda, Yuta Norimatsu, Ai Kuzumi, Ayumi Yoshizaki
Zitieren
APA
Matsuda, K. M., Sugimoto, E., Ako, Y., Kitamura, M., Miyahara, M., Kotani, H., Norimatsu, Y., Hisamoto, T., Kuzumi, A., Fukasawa, T., Sato, S., & Yoshizaki, A. (2024). Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17202
Vancouver
Matsuda KM, Sugimoto E, Ako Y, Kitamura M, Miyahara M, Kotani H, et al. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17202
BibTeX
@article{Matsuda2024,
author = {Matsuda, Kazuki M and Sugimoto, Eiki and Ako, Yoshiaki and Kitamura, Marie and Miyahara, Mai and Kotani, Hirohito and Norimatsu, Yuta and Hisamoto, Teruyoshi and Kuzumi, Ai and Fukasawa, Takemichi and Sato, Shinichi and Yoshizaki, Ayumi},
title = {Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17202}
}
EUVIMED